On June 5, 2026, a delegation led by Professor Lo Chung-mau, Secretary for Health of the Hong Kong Special Administrative Region, visited Xiamen Bio Bay and Xiamen Innovax Biotech Co., Ltd. (IX), accompanied by representatives from the Fujian Provincial Health Commission. The visit focused on biomedical innovation, vaccine R&D translation, clinical research collaboration, and international development.

Recently, the prequalification (PQ) application for Cecolin 9, the HPV 9-valent vaccine, was formally submitted to the World Health Organization (WHO). In accordance with relevant procedures, WHO will subsequently conduct dossier screening, technical assessment and manufacturing site inspection before making a final decision on whether to grant prequalification.

Recently, China Close-Up, a feature column by Xinhuanet, highlighted a standout case of Chinese HPV vaccine technology going globally, showcasing the collaboration among Xiamen Innovax Biotech Co., Ltd. (IX )， Thailand’s National Vaccine Institute (NVI), Chulalongkorn University and Global Biotech Products Co., Ltd. (GBP) in the field of HPV vaccines.

On January 27, 2026, Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. announced that its wholly owned subsidiary, Xiamen Innovax Biotech Co., Ltd. (“Innovax”), has maintained compliance with the World Health Organization (WHO) Prequalification (PQ) standards following a periodic re-inspection conducted by the WHO Prequalification Inspection Team (WHO PQT–INS) of its bivalent HPV vaccine, Cecolin. The vaccine was initially prequalified by WHO in 2021, and this re-inspection reaffirms its continued compliance with international quality standards.

At Xiamen Innovax, women are playing a leading role in advancing vaccine innovation and expanding access to cervical cancer prevention. This commitment was recently recognized when the company received the National March 8th Red-Banner Collective, a national honor awarded by the All-China Women's Federation to organizations demonstrating outstanding contributions by women. The recognition highlights the important role women play across Xiamen Innovax’s research, manufacturing, and quality teams—and their contributions to the development of innovative HPV vaccines designed to protect women’s health.

Thailand, Dec. 4, 2025 — Xiamen Innovax Biotech Co., Ltd. (INNOVAX) and Thailand’s National Vaccine Institute (NVI) jointly served as witnesses to Global Biotech Products Co., Ltd. (GBP) being awarded the Thailand Triple S Awards 2025 (Science, Society and Sustainability) by the Thailand Science Research and Innovation Agency (TSRI), an honor unveiled as part of the Thailand SRI Index 2025. This milestone recognizes the joint efforts of INNOVAX and GBP in the 9-valent HPV vaccine technology-transfer project, with strong support from NVI.